Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the mainstay of treatment for prostate cancer and are routinely used across lines. Zytiga (Johnson & Johnson / Janssen Biotech / Janssen-Cilag / AstraZeneca) and Xtandi (Pfizer / Astellas) are cornerstone treatments for metastatic castrate-resistant prostate cancer (mCRPC). Several current and emerging therapies are also being positioned in the lucrative nonmetastatic CRPC and metastatic hormone-sensitive settings. The late-phase pipeline for mCRPC has also become more dynamic, with four PARP inhibitors (AstraZeneca / Merck Sharp and Dohme’s Lynparza, Clovis Oncology’s Rubraca, Johnson & Johnson’s Zejula, and Pfizer’s Talzenna), four immune checkpoint inhibitors (Bristol-Myers Squibb/Ono Pharmaceutical’s Opdivo, Bristol-Myers Squibb/Ono Pharmaceutical’s Yervoy, Merck Sharp and Dohme’s Keytruda, and Roche/Genentech/Chugai’s Tecentriq), one kinase inhibitor (Array BioPharma / Roche / Genentech / Chugai’s ipatasertib), and one radioligand therapy (Novartis’ 177Lu-PSMA-617) in Phase III development.

Questions Answered

  • What factors are driving and constraining market growth? Which new classes of agents will emerge over the forecast period, and what impact will they have on the overall market?
  • How is prostate cancer currently managed, and how will treatment practices change in the future?
  • What is the clinical and commercial potential of late-phase pipeline products, and what will be their likely positioning in the market? How will new market entrants fare through 2028?
  • What are the actionable remaining unmet needs affecting the management of prostate cancer? What are the key drug development and therapeutic opportunities?

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: More than 20 country-specific interviews with thought-leading medical oncologists, supported by survey data collected for this and other DRG research.

Key companies: Johnson & Johnson, Janssen Biotech, Janssen-Cilag, AstraZeneca, Pfizer, Astellas Pharma, Sanofi, Roche, Bayer HealthCare, Clovis Oncology, Merck Sharp & Dohme.

Key drugs: Xtandi (enzalutamide), Zytiga (abiraterone), Erleada (apalutamide), Xofigo (radium-223), Jevtana (cabazitaxel), docetaxel, Yonsa (abiraterone acetate), Nubeqa (darolutamide), Lynparza (olaparib), Rubraca (rucaparib), Talzenna (talazoparib), Zejula (niraparib), Tecentriq (atezolizumab), Keytruda (pembrolizumab), Opdivo (nivolumab), Yervoy (ipilimumab), ipatasertib, relugolix, 177Lu-PSMA-617.

Product Description

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • COVID-19
    • Key Findings
      • Prostate Cancer Key Findings
    • Key Updates
      • April 2020
      • November 2019
      • August 2019
      • May 2019
    • Market Outlook
      • Key Findings
      • COVID-19: Areas of Potential Forecast Impact
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Prostate Cancer?
        • What Factors Are Constraining the Market for Prostate Cancer?
      • Segment-Specific Trends
        • Hormone-Sensitive Prostate Cancer
        • Nonmetastatic Castrate-Resistant Prostate Cancer
        • First-Line Metastatic Castrate-Resistant Prostate Cancer
        • Second- and Subsequent-Line Metastatic Castrate-Resistant Prostate Cancer
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Key Findings
        • Disease Overview
      • Disease Pathophysiology
        • Biology and Metastatic Spread of Prostate Cancer
        • Prostate-Specific Antigen
        • Staging Classification and Grading Systems for Prostate Cancer
        • Development of Castrate-Resistant Prostate Cancer
      • Key Pathways and Drug Targets
        • Androgen Receptor Signaling Pathway
        • Splice Variants of the Androgen Receptor
        • Emerging Drug Targets in Prostate Cancer
    • Epidemiology
      • Introduction
        • Key Findings
      • Epidemiology Populations
        • Newly Diagnosed Incident Cases
        • TNM Stage Distribution and NCCN Risk Category
        • Recurrent Incident Cases
        • Drug-Treatable Populations
        • Drug-Treated Populations
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Hormonal Agents
        • Immunotherapies
        • Bone Metastases-Targeted Agents
        • Cytotoxic Agents
      • Medical Practice
        • Newly Diagnosed, Low- and Intermediate-Risk Hormone-Sensitive Prostate Cancer
        • Newly Diagnosed, High- and Very-High-Risk Hormone-Sensitive Prostate Cancer
        • Newly Diagnosed, Metastatic Hormone-Sensitive Prostate Cancer
        • Biochemically Recurrent Prostate Cancer
        • Nonmetastatic Castrate-Resistant Prostate Cancer
        • First-Line Metastatic Castrate-Resistant Prostate Cancer
        • Second- and Subsequent-Line Metastatic Castrate-Resistant Prostate Cancer
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Prostate Cancer
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Hormonal Agents
        • Immunotherapies
        • PARP Inhibitors
        • Kinase Inhibitors
        • PSMA-Targeted Radioligands
      • Early-Phase Pipeline Analysis
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug- and Regimen-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Cycles of Therapy, and Compliance
        • Generic Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Prostate Cancer Bibliography

Author(s): Carolina do Pazo, M.Sc; Narendra Parihar

Carolina do Pazo, is a Business Insights Analyst in the oncology division at Decision Resources Group. Prior to joining DRG, she completed a MSc in Biotechnology, Bioprocessing and Business Management with distinction at the University of Warwick, as a Chevening scholar. She also earned her first-class BSc and BEng in Biotechnology from the Universidad ORT. Ms. do Pazo has worked as a Research Scientist at the Institut Pasteur de Montevideo, analysing the ageing process of yeast cells, and has been part of a project between Indiana University and Universidad ORT that analysed the production of nanohybrids for drug delivery systems applications.

Narendra is an associate epidemiologist within the epidemiology team at Decision Resources Group. Narendra specializes in developing epidemiological forecasts for multiple indications within the DRG syndicated portfolio. His qualifications include an MPH with specialization in Health Policy, Economics and Finance from the Tata Institute of Social Sciences, Mumbai, and a Bachelor’s degree in Dentistry from the Rajasthan University of Health Sciences.

Related Reports

Prostate Cancer | Disease Landscape and Forecast | G7 | 2019

Market Outlook Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the main treatment for prostate cancer and are routinely used...

View Details

Prostate Cancer | Current Treatment | Detailed, Expanded Analysis (US)

Hormonal therapies have dominated the treatment of prostate cancer for the past decade. Zytiga (Janssen, generics) and Xtandi (Medivation / Astellas Pharma), initially approved for metastatic cas...

View Details